The acronym “EPIsoDE” (Efficacy and safety of Psilocybin In treatment-reSistant majOr DEpression) summarizes the aim of the study: To investigate whether psilocybin administered under supportive conditions in a controlled, randomized, double-blind design is a safe and effective treatment for depression patients whose symptoms cannot be adequately reduced with antidepressants. Over the course of the study, 144 patients will be treated in Mannheim and Berlin. The rationale and study design are explained in detail in a recent article published in the scientific journal Neuroscience Applied.
The EPIsoDE Study’s official website provides further information (in German language), including directions for potential study participants and referring physicians.